<DOC>
	<DOCNO>NCT00364819</DOCNO>
	<brief_summary>The purpose study determine safety anti-CD20 antibody rituximab treat patient Primary Biliary Cirrhosis ( PBC ) . Rituximab laboratory-made antibody currently use treat kind lymphoma . Rituximab may also help people PBC , disease immune system . However , safety rituximab PBC patient must first establish .</brief_summary>
	<brief_title>Initial Study Rituximab Treat Primary Biliary Cirrhosis</brief_title>
	<detailed_description>This pilot , open-label , study 10 female patient AMA-positive PBC determine effect two infusion rituximab response memory B cell bacterial motif , biochemical function , histological feature . We enroll 10 consecutive AMA-positive patient diagnosis PBC base internationally accepted criterion histological staging determine liver biopsy currently treat UDCA . Importantly , patient advance histological stage , decompensated liver disease , wait OLT include study ( see exclusion criterion ) . Patients eligible willing enter study evaluate baseline isolation study frequency absolute number B cell function , biochemical AMA test . Histology quality life also evaluate patient . The methodology use B cell study already well-established laboratory see attach paper ( Kikuchi et al . 2005b ) . Patients administer 1,000 mg rituximab intravenously slow infusion Day 1 Day 15 ( +/- 1 day ) . Rituximab 's pharmacokinetics indicate complete B cell depletion obtain 2-3 day administration effect may lose 9 month ( Vieira et al . 2004 ) . In addition B cell work , serum sample undergo AMA testing , include titer , use recombinant mitochondrial antigen ( Miyakawa et al . 2001 ) . Patients also undergo serum chemistry panel , include liver function test . Patients continue steady dose UDCA therapy throughout study .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Liver biopsy show histological PBC stage I , II , III Presence criterion diagnosis PBC serum AMA titer &gt; 1:40 alkaline phosphatase &gt; 2X normal value &gt; 6 month compatible liver histology Incomplete response UDCA 6 month treatment . Negative pregnancy test ( female patient fertile age ) Adequate renal function ( serum creatinine &lt; 1.2 ) Endstage/decompensated liver disease ascites jaundice serum bilirubin &gt; 2mg/dl history digestive bleeding secondary portal hypertension endoscopic evidence varix stage F2 history hepatic encephalopathy INR &gt; 1.2 Other coexist cause liver disease Use immunosuppressive medication 4 week prior enrollment Diuretics use</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Primary Biliary Cirrhosis</keyword>
</DOC>